Weixinkang (603676.SH) subsidiary succinyl gelatin electrolyte sodium acetate injection approved for clinical trials

Zhitongcaijing · 5d ago

Zhitong Finance App News, Wei Xinkang (603676.SH) issued an announcement. Recently, Inner Mongolia Baiyi Pharmaceutical Co., Ltd. (“Baiyi Pharmaceutical”), a wholly-owned subsidiary of the company, received the approval and issuance of the “Drug Clinical Trial Approval Notice” for succinyl gelatin electrolyte sodium acetate injections issued by the State Drug Administration (“State Drug Administration”).

The succinyl gelatin electrolyte sodium acetate injection declared by Baiyi Pharmaceutical, a wholly-owned subsidiary of the company, was developed using Succinylated Electrolytes Injection certified by B.Braun Melsungen AG as a reference preparation. This product is used as a colloidal plasma volume substitute dissolved in an isotonic electrolyte balanced solution, and is used for the treatment of: 1. Relative or absolute hypovolemia and shock. 2. Combined medication with crystal solution as a component of the perfusion solution participates in the extracorporeal circulation process (e.g., cardiopulmonary machine).